Managing Director Diane Wehner of Teton Advisors says Alexion Pharmaceuticals, Inc. (ALXN) is a high-growth company with proprietary technology that’s been growing its revenues above 40% for the last five years.
“[Alexion is] a biotech company with sales of $1.5 billion in 2013,” Wehner said. “They generate revenues from a commercialized drug called Soliris, which is an antibody drug that treats rare diseases. This is the focus of the company…Soliris is literally a wonder drug that saves patients’ lives.”
FOR MORE INFORMATION ON THIS INTERVIEW CLICK HERE.
As a result, Alexion has huge barriers to entry and competitive advantages, Wehner says. The company has also acquired other drugs in the orphan disease space, opening up further opportunities.
“The company has taken the profits generated from Soliris and they’ve acquired additional drugs that target rare diseases creating a pipeline of opportunities for the next several years…The portfolio has benefited from owning the stock over the last five years, which has appreciated over 771%. It’s been an enormous investment for us,” Wehner said.
Candida Auris Cure Approved? Dr. Taglietti of Scynexis Details the Development of this New Wonder Drug
April 15, 2019
Pamela Palmer, M.D., Ph.D., Has Developed a New Wonder Drug for her Company
October 10, 2019
IHS Inc. (IHS) has Unmatched Franchise Value with 75% Recurring Revenues
March 18, 2014
Tessera Technologies, Inc. (TSRA) Attractively Priced Given Growth Prospects and Recurring Revenues
April 01, 2015
CME Group (CME) Revenues to Accelerate When Interest Rates Rise; Will Benefit from Regulation of OTC Derivatives
April 02, 2013
